menu
    • menu
    [{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Epinephrine","moa":"||Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Epinephrine","moa":"||Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"||Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Financing","leadProduct":"Epinephrine","moa":"||Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Bryn Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Epinephrine","moa":"||Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Bryn Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Bryn Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bryn Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Bryn Pharma

    Menu

    Bryn Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bryn Pharma’s UTULY™ 13.2mg Intranasal Epinephrine Spray Provides Higher and More Sustained PK Compared to...

                            Details : Utuly (epinephrine) is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.

                            Product Name : Utuly

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            February 24, 2023

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bryn Pharma Announces Completion of its Pivotal Study Comparing UTULY™ Epinephrine Intranasal Spray vs. 0.3 ...

                            Details : Utuly, an epinephrine nasal spray, for the treatment of anaphylaxis. It is designed to provide patients with a life-saving treatment that is needle free, fits in a pocket, is easy to use, and complies with practice parameters.

                            Product Name : Utuly

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            September 13, 2022

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bryn Pharma Publishes Positive Results from Its Intranasal Epinephrine Preclinical Study Program In Three Peer...

                            Details : The preclinical results described in the publications were used to support the advancement of BRYN-NDS1C into the human clinical trial program currently underway.

                            Product Name : Utuly

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            October 06, 2020

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bryn Pharma Presents Data Demonstrating Comparable Pharmacokinetic and Pharmacodynamic Effects of Intranasal E...

                            Details : Intranasal (IN) delivery of epinephrine from Bryn's needle-free Bi-dose Epinephrine Nasal Spray was comparable to intramuscular (IM) injection in pharmacokinetics, pharmacodynamics, and safety.

                            Product Name : Utuly

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            June 04, 2020

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Bryn Pharma

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $26.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Bryn Pharma Raises $11 Million in Financing to Advance Bi-Dose Epinephrine Nasal Spray for Anaphylaxis

                            Details : Proceeds from the financing will be used to fund the remaining development and regulatory approval activities, and pre-launch commercialization program for BRYN-NDS1C, Bryn's bi-dose epinephrine nasal spray.

                            Product Name : Utuly

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            April 08, 2020

                            Lead Product(s) : Epinephrine,Inapplicable

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : $26.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth